A study of SGN-CEACAM5C in adults with advanced solid tumors
Phase 1
Recruiting
- Conditions
- on-small cell lung cancer – squamous, Pancreatic carcinoma, Gastric cancer, Gastroesophageal junction adenocarcinoma, Small cell lung cancer, Colorectal cancer, Non-small cell lung cancer – nonsquamousMedDRA version: 21.1Level: PTClassification code: 10061873Term: Non-small cell lung cancer Class: 100000004864MedDRA version: 21.0Level: PTClassification code: 10061451Term: Colorectal cancer Class: 100000004864MedDRA version: 21.1Level: PTClassification code: 10041067Term: Small cell lung cancer Class: 100000004864MedDRA version: 21.0Level: PTClassification code: 10033609Term: Pancreatic carcinoma Class: 100000004864MedDRA version: 26.1Level: PTClassification code: 10041826Term: Squamous cell carcinoma of lung Class: 100000004864MedDRA version: 21.0Level: PTClassification code: 10030137Term: Oesophageal adenocarcinoma Class: 100000004864MedDRA version: 21.1Level: PTClassification code: 10017758Term: Gastric cancer Class: 100000004864Therapeutic area: Diseases [C] - Neoplasms [C04]
- Registration Number
- CTIS2023-505858-18-00
- Lead Sponsor
- Seagen Inc.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 410
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method